
Dermata Therapeutics fell 80.5% from $2.61 to $0.51, behind the S&P 500's +4.7%. Its worst day was Feb 20 (−30.1%), and its low came Nov 20 at $0.51.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Dermata Therapeutics closed at its highest level of the year, 20.3% above where the year started.
+3.6% · S&P 500 +0.5%
Dermata Therapeutics shares rose 22.6%, while the S&P 500 fell 0.1%.
Story events cover the past 12 months · Times ET
+22.6% · S&P 500 −0.1%
Dermata Therapeutics shares rose 41.9%, while the S&P 500 rose 0.5%.
+41.9% · S&P 500 +0.5%
Dermata Therapeutics shares rose 50.8%, while the S&P 500 fell 0.3%.
+50.8%, the year's best day · S&P 500 −0.3%
EPS of $-1.52 beat the $-1.54 estimate on $0.00 revenue.
−13.9% · S&P 500 −1.7%
EPS of $-0.48 beat the $-0.53 estimate on $0.00 revenue.
+3.4% · S&P 500 +0.8%
EPS of $-0.74 missed the $-0.55 estimate on $0.00 revenue.
+27.8% · S&P 500 +0.3%
Dermata Therapeutics shares rose 45.4%, while the S&P 500 rose 0.3%.
+45.4%, on 171M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-0.55 beat the $-0.55 estimate on $0.00 revenue (est. $25,000.00).
+0.1% · S&P 500 +1.3%
Where it ended: a close of $0.51 on Nov 20, 2026.
Nothing in the past 12 months.
All DRMA analyst actionsNothing in the past 12 months.
All DRMA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DRMA and SPY from Benzinga historical bars. Not investment advice.